PA8652101A1 - Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados - Google Patents

Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados

Info

Publication number
PA8652101A1
PA8652101A1 PA20058652101A PA8652101A PA8652101A1 PA 8652101 A1 PA8652101 A1 PA 8652101A1 PA 20058652101 A PA20058652101 A PA 20058652101A PA 8652101 A PA8652101 A PA 8652101A PA 8652101 A1 PA8652101 A1 PA 8652101A1
Authority
PA
Panama
Prior art keywords
piridine
compositions
compounds
related methods
imidazo compounds
Prior art date
Application number
PA20058652101A
Other languages
English (en)
Spanish (es)
Inventor
Albert Palomer
Jose Luis Falco
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of PA8652101A1 publication Critical patent/PA8652101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PA20058652101A 2004-11-11 2005-11-08 Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados PA8652101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11

Publications (1)

Publication Number Publication Date
PA8652101A1 true PA8652101A1 (es) 2006-10-13

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058652101A PA8652101A1 (es) 2004-11-11 2005-11-08 Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados

Country Status (24)

Country Link
US (1) US20080200473A1 (https=)
EP (1) EP1814880B1 (https=)
JP (1) JP2008519805A (https=)
KR (1) KR20070084026A (https=)
CN (1) CN101065377B (https=)
AR (1) AR051626A1 (https=)
AT (1) ATE421962T1 (https=)
AU (1) AU2005303811A1 (https=)
BR (1) BRPI0517796A (https=)
CA (1) CA2585315A1 (https=)
DE (1) DE602005012598D1 (https=)
DK (1) DK1814880T3 (https=)
ES (1) ES2321858T3 (https=)
IL (1) IL182963A0 (https=)
MX (1) MX2007005611A (https=)
NO (1) NO20072831L (https=)
PA (1) PA8652101A1 (https=)
PE (1) PE20060967A1 (https=)
PL (1) PL1814880T3 (https=)
PT (1) PT1814880E (https=)
RU (1) RU2007121864A (https=)
TW (1) TWI357412B (https=)
UY (1) UY29204A1 (https=)
WO (1) WO2006051063A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
AU2007267183B2 (en) * 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
CN101528226B (zh) * 2006-08-24 2012-01-11 澳大利亚核科学技术组织 靶向外周苯二氮卓受体的氟化配体
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
CA2724842A1 (en) * 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
US10478438B2 (en) 2008-10-16 2019-11-19 David Reed Helton Treatment of organophosphate exposure with ocinaplon
US20120010188A1 (en) * 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
EP2496578A4 (en) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230121497A1 (en) * 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3167275A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
CN118515663A (zh) * 2023-04-24 2024-08-20 上海赛默罗生物科技有限公司 咪唑并吡啶或咪唑并吡嗪类化合物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ATE62687T1 (de) * 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
US20040204443A1 (en) * 2003-01-27 2004-10-14 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
EP1814880A1 (en) 2007-08-08
AR051626A1 (es) 2007-01-24
CN101065377B (zh) 2011-07-27
UY29204A1 (es) 2006-01-31
PE20060967A1 (es) 2006-09-20
CA2585315A1 (en) 2006-05-18
MX2007005611A (es) 2007-07-11
EP1814880B1 (en) 2009-01-28
DE602005012598D1 (de) 2009-03-19
TW200624432A (en) 2006-07-16
PL1814880T3 (pl) 2009-07-31
ATE421962T1 (de) 2009-02-15
IL182963A0 (en) 2007-08-19
WO2006051063A1 (en) 2006-05-18
RU2007121864A (ru) 2008-12-20
BRPI0517796A (pt) 2008-10-28
PT1814880E (pt) 2009-04-23
TWI357412B (en) 2012-02-01
AU2005303811A1 (en) 2006-05-18
CN101065377A (zh) 2007-10-31
ES2321858T3 (es) 2009-06-12
US20080200473A1 (en) 2008-08-21
KR20070084026A (ko) 2007-08-24
JP2008519805A (ja) 2008-06-12
DK1814880T3 (da) 2009-05-18
NO20072831L (no) 2007-08-01

Similar Documents

Publication Publication Date Title
PA8652101A1 (es) Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
EA201170771A1 (ru) Органические соединения
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
MA47500B1 (fr) Dérivés de pyrrolo[1,2-b]pyridazine
ECSP099400A (es) Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
ECSP088413A (es) Preparación y uso de derivados de tetrahidropirrolo[3,2-c]piridin-4-ona para el tratamiento de la obesidad, trastornos psiquiátricos y neurológicos
UY28144A1 (es) Agentes terapéuticos
CR9389A (es) Compuestos de imidazopiridazina
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
CR10682A (es) Compuestos de tiazol pirazolopirimidina
CR7932A (es) Pirazolo (1,5-a) (1,3,5) derivados de triazina como ligandos de receptor de cannabinoides
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
PE20091056A1 (es) PIRIDO[3,2-e]PIRAZINAS, SU PROCEDIMIENTO DE PREPARACION Y USO COMO INHIBIDORES DE FOSFODIESTERASA 10
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
NI200800021A (es) Derivados de n - (arilalquil) - 1h - pirrolopiridin - 2 - carboxamidas, su preparación y su aplicación en terapéutica
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos
CR8094A (es) Derivados de imidazol antagonistas del receptor de glutamato